SCHEMBL22333992

SCHEMBL22333992

CC1(C)OC2C(CCOCc3ccccc3)[C@@H](COC(=O)c3ccccc3)O[C@@H]2O1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.67
HPGD P15428 2/20 0.53
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
MAPK1 P28482 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.36
TACR2 P21452 3/20 0.35
NT5E P21589 1/20 0.35
MAPT P10636 1/20 0.35
SLC22A1 O15245 1/20 0.35
FOLH1 Q04609 2/20 0.35
CES2 O00748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22901905 1.00 ALDH1A1 (0.67) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL29558108 1.00 ALDH1A1 (0.67) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL4953659 0.92 ALDH1A1 (0.69) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL10432003 0.90 ALDH1A1 (0.66) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL26209791 0.89 ALDH1A1 (0.68) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL26209710 0.86 ALDH1A1 (0.64) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL17198419 0.86 ALDH1A1 (0.80) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL22333926 0.84 ALDH1A1 (0.46) ALDH1A1HPGDPOLBSLC6A2KMT2A
SCHEMBL22333927 0.84 ALDH1A1 (0.46) ALDH1A1HPGDPOLBSLC6A2KMT2A
SCHEMBL17198635 0.84 ALDH1A1 (0.77) ALDH1A1HPGDPOLBGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340613-A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE IMMUNESENSOR THERAPEUTICS, INC. 2022-10-27 US disclosed
US-11213592-B2 Antibody-sting agonist conjugates and their use in immunotherapy IMMUNESENSOR THERAPEUTICS, INC. (US) 2022-01-04 US disclosed
US-20210290774-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-09-23 US disclosed
US-11033635-B2 Antibody-STING agonist conjugates and their use in immunotherapy IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-06-15 US disclosed
WO-2021016204-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-01-28 WO disclosed
US-20210015941-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY IMMUNESENSOR THERAPEUTICS, INC. (US) 2021-01-21 US disclosed
EP-3692996-A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE Immune Sensor, LLC (US) 2020-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11213592-B2 Antibody-sting agonist conjugates and their use in immunotherapy STING1, CGAS, MAVS ALDH1A1 4589/4885HPGD 3490/4885POLB 1958/4885
US-20210290774-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY STING1, CGAS, MAVS ALDH1A1 4589/4885HPGD 3490/4885POLB 1958/4885
US-20220340613-A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE CGAS, PDE7A, PDE11A ALDH1A1 3411/4885HPGD 201/4885POLB 100/4885
US-11033635-B2 Antibody-STING agonist conjugates and their use in immunotherapy STING1, CGAS, MAVS ALDH1A1 4589/4885HPGD 3490/4885POLB 1958/4885
US-20210015941-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY STING1, CGAS, MAVS ALDH1A1 4589/4885HPGD 3490/4885POLB 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.